Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 2 - Caught on Camera

Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For

Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.

Benzinga

Moderna Stock Soars More Than 100% on Cancer Vaccine Breakthrough: What Investors Are Betting On

Moderna shares surged after its personalised mRNA cancer treatment met key Phase 3 trial endpoints in melanoma with Merck's Keytruda.

International Business Times UK

Stocks Finish Mixed as Bond Yields Fall and Chipmakers Slide

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.21% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.22%. E-mini S&P futures (ESU26 ) rose +0.20%, and September E-mini...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Snap Losing Streak as Treasury Yields Ease: Stock Market Today

Yields on the 10-year and 30-year Treasuries pulled back Wednesday after the Treasury Department announced new buyback levels.

Kiplinger

Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made

Moderna Inc. (NASDAQ:MRNA) stock soared Wednesday after the company and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, marking a major milestone for the emerging technology. Shares jumped more than 100%, reaching levels not seen since May 2024.

Benzinga

US stocks: US market rises as yields ease, Moderna lifts healthcare stocks

US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimistic. The Treasury's announcement of liquidity support revitalized riskier assets, particularly in tech…

The Economic Times

'Breakthrough' mRNA cancer drug curbs melanoma in large trial

WASHINGTON (UNITED STATES) - US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough."

Bangkok Post

Read news from The Economist, FT, and more,
with one subscription

Breakthrough Personalized mRNA Vaccines Are Highly Effective Against Melanoma Skin Cancers

The vaccine could be available as soon as 2027.

Reason

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Fortune

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

U.S. equities clawed back Tuesday’s tech-led slump by midday Wednesday as the Treasury’s decision to double its long-dated debt buybacks pulled benchmark yields off 20-month highs and knocked the dollar to its weakest level since late May.

Benzinga

This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results

Moderna stock rips higher on a major cancer breakthrough. The announcement led William Blair to upgrade MRNA shares to "Outperform."

Barchart

Moderna stock more than doubles after skin cancer breakthrough announcement

IN FULL

The Independent UK

Moderna Shares Double Overnight Because a Made-to-Order mRNA Vaccine Actually Beats Skin Cancer

Moderna's personalised mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence in a Phase 3 trial, doubling the company's stock value and marking a milestone in cancer treatment.

International Business Times UK

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) is up by +0.58% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.07%. E-mini S&P futures (ESU26 ) are up +0.61%, and September E-mini...

International Business Times

Possible Skin Cancer Vaccine Shows Promise In Late Stage Trial. Moderna Stock Skyrockets.

The late-stage clinical trial was described as a "landmark moment."

The Economic Times

Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are…

Barchart

Stocks Mixed on Lower Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is up by +0.33% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.33%. E-mini S&P futures (ESU26 ) are up +0.31%, and September E-mini...

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Skin cancer vaccine shows promise in preventing recurrence of melanoma in large trial

IN FULL

The Economic Times

US stocks: US market regains ground as bond yields ease; healthcare stocks rally

Major stock indexes recovered on Wednesday after a prior day's decline. Moderna shares surged significantly following positive cancer therapy trial results. Government bond yields eased from highs, boosting investor risk appetite. Retailers like Target and Lowe's reported quarterly results, influencing consumer spending views. Geopolitical developments and Federal Reserve minutes remained…

The Independent UK

Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning

More than 8,500 Americans are expected to die of melanoma this year

Medical Daily

Moderna Begins First Human Trial of a Vaccine for the Ebola Strain Driving Congo's Outbreak

Moderna started a phase 1 trial of an mRNA vaccine against Bundibugyo ebolavirus, a strain for which no vaccine is approved, that is driving an outbreak in Congo.

Medical Daily

The First mRNA Flu Vaccine Is Approved, and What Changes for Patients Is Not Simply Another Shot Option

The FDA approved mFlusiva for adults 50 and older. Here is who qualifies, how mRNA flu shots differ, and what still stands before they become widely available.

Medical Daily

FDA Approves First mRNA Flu Shot for Adults 50 and Older Ahead of the 2026–2027 Season

FDA approved mFLUSIVA, the first mRNA flu vaccine, for adults 50 and older. Here is what it means for fall shots, timing, and access.

The Conversation

First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Treasury Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.